document
June 1, 2012 — 00:00
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
373
-
-
documentJune 1, 2012 — 00:00
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
-
documentMay 3, 2012 — 00:00
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
-
documentMay 3, 2012 — 00:00
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
-
documentMay 3, 2012 — 00:00
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
-
documentMay 3, 2012 — 00:00
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
-
documentMay 2, 2012 — 00:00
A.M. Best has upgraded the Issuer Credit Ratings (ICR) of SCOR SE and its main subsidiaries from “a” to “a+”. They have also affirmed the Financial Strength Ratings of “A” (Excellent).
-
documentMarch 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011
-
documentMarch 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
-
documentMarch 8, 2012 — 00:00
SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.
-
documentFebruary 9, 2012 — 00:00
SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.
-
documentFebruary 1, 2012 — 00:00
Life insurers are cautious about integrating medical and technological advances into their underwriting procedures in order to avoid unintended consequences to decision accuracy.
